source
- Sling Therapeutics raises $123M Series C to advance oral thyroid eye disease drug into Phase 3Sling Therapeutics announced a $123 million Series C financing round aimed at moving its oral therapy for thyroid eye disease into a late‑stage trial and eventual market launch. The company has be…
- FDA launches Operation TrialBlazer to accelerate early-stage drug trials and bring research back to the U.S.The FDA announced it is now accepting applications for Operation TrialBlazer, an expedited IND pilot program. The program pairs drug sponsors with qualified U.S. research institutions to cut the r…